GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Tirofiban

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Aggrastat

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Aggrastat - product and source limitations

Calculate Cockcroft-Gault with actual body weight. The renal reduction affects the infusion; confirm concentration and monitor bleeding and platelets.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Aggrastat - product and source limitations

Official source

Aggrastat - labeled renal guidance

Renal action and limits

Tirofiban (Aggrastat), adult IV treatment of non-ST-elevation acute coronary syndrome
Cockcroft-Gault CrCl using actual body weight, mL/min

Action or finding
At CrCl <=60 mL/min, give 25 mcg/kg IV within 5 minutes, then 0.075 mcg/kg/min for up to 18 hours.
Limits and monitoring
Calculate Cockcroft-Gault with actual body weight. The renal reduction affects the infusion; confirm concentration and monitor bleeding and platelets.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 3, effective 2025-01-01; posted Dec 26, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage All evidence
Product / population
Tirofiban (Aggrastat), adult IV treatment of non-ST-elevation acute coronary syndrome
Renal measure
Cockcroft-Gault CrCl using actual body weight, mL/min
Source revision
DailyMed SPL version 3, effective 2025-01-01; posted Dec 26, 2024
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal guidance: 2.3 and 8.6

At CrCl <=60 mL/min, give 25 mcg/kg IV within 5 minutes, then 0.075 mcg/kg/min for up to 18 hours. Calculate Cockcroft-Gault with actual body weight. The renal reduction affects the infusion; confirm concentration and monitor bleeding and platelets.

Source revision: DailyMed SPL version 3, effective 2025-01-01; posted Dec 26, 2024 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e850111f-e713-41a2-9c65-21c517cf5511

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Aggrastat - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Tirofiban (Aggrastat), adult IV treatment of non-ST-elevation acute coronary syndrome

Renal method: Cockcroft-Gault CrCl using actual body weight, mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Aggrastat - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Tirofiban (Aggrastat), adult IV treatment of non-ST-elevation acute coronary syndrome

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Aggrastat - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Aggrastat - product and source limitations

Calculate Cockcroft-Gault with actual body weight. The renal reduction affects the infusion; confirm concentration and monitor bleeding and platelets.

How to use this: Apply only to the stated formulation, indication and renal population.

Aggrastat - labeled renal guidanceAggrastat - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAggrastat - labeled renal guidanceAggrastat - selected RX renal passage
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/tirofiban/

Indication and usual adult dose

AGGRASTAT for non-ST-elevation acute coronary syndrome reduces the combined thrombotic cardiovascular endpoint of death, MI, refractory ischemia or repeat cardiac procedure. IV only: 25 micrograms/kg within 5 minutes, then 0.15 micrograms/kg/min for up to 18 hours.

GRPH-tirofiban-01 · Source section: Indication and usual adult doseRenal section finder

Original preparation and compatibility instructions

Inspect for particles/discoloration; use only clear solution with intact seal. Remove the INTRAVIA foil overpouch; temporary plastic opacity from sterilization moisture may diminish. Squeeze the inner bag to check for leaks; discard if leaking or sterility is questionable. Do not connect bags in series because of air-embolism risk.

Withdraw the bolus from the 15 mL premixed bolus vial, or use the 100 mL premixed vial/bags. Do not dilute. Administer by syringe or IV pump within 5 minutes, then immediately begin maintenance from the 100 mL vial/bag using a pump. Discard remaining solution.

Bolus volume: 25 micrograms/kg x body weight / 250 micrograms/mL for the 15 mL vial, or divide by 50 micrograms/mL for the 100 mL vial/bag.

For CrCl above 60, maintenance mL/hour = 0.15 micrograms/kg/min x weight x 60 / 50 micrograms/mL.

The original same-line compatibility list includes heparin, atropine sulfate, dobutamine, dopamine, epinephrine HCl, famotidine injection, furosemide, lidocaine, midazolam HCl, morphine sulfate, nitroglycerin, potassium chloride and propranolol HCl. Do not share the line with diazepam. Do not add drugs to, or withdraw solution directly with a syringe from, the INTRAVIA bag.

GRPH-tirofiban-02 · Source section: Original preparation and compatibility instructionsRenal section finder

Renal Dosing

CrCl at or below 60 mL/min: unchanged 25 micrograms/kg bolus within 5 minutes, then 0.075 micrograms/kg/min for up to 18 hours.

At 50 micrograms/mL, renal-adjusted mL/hour = 0.075 micrograms/kg/min x weight x 60 / 50 micrograms/mL.

GRPH-tirofiban-03 · Source section: Renal DosingRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Aggrastat - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Tirofiban (Aggrastat), adult IV treatment of non-ST-elevation acute coronary syndrome

Renal method: Cockcroft-Gault CrCl using actual body weight, mL/min
Source date: DailyMed SPL version 3, effective 2025-01-01; posted Dec 26, 2024
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.3 and 8.6

At CrCl <=60 mL/min, give 25 mcg/kg IV within 5 minutes, then 0.075 mcg/kg/min for up to 18 hours. Calculate Cockcroft-Gault with actual body weight. The renal reduction affects the infusion; confirm concentration and monitor bleeding and platelets.

RDM73-aggrastat-official-1 · Source locator: Renal guidance: 2.3 and 8.6

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e850111f-e713-41a2-9c65-21c517cf5511
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault CrCl using actual body weight, mL/min
Source date/version
DailyMed SPL version 3, effective 2025-01-01; posted Dec 26, 2024
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
24150be4ff60599f6c7c8aad7fc0bc69b0e9d46754412bb7a862af67a2e3340c
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Aggrastat - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Tirofiban (Aggrastat), adult IV treatment of non-ST-elevation acute coronary syndrome

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror supplies separate bolus and infusion instructions and a renal-adjusted infusion rate.

RDM73-aggrastat-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/aggrastat-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
5b4529b0983507085b6e1f50e0a4c003ce16203a3005a2ac8e8e1bf870fa4c5c

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/tirofiban/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
fc0a9e772527a70c53f40fa3e16fb70b2e1fc2246a5d8bf487a5a46f1613a9a8
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top